Moderna’s (NASDAQ: MRNA) share price has more than doubled this year as the market has grown increasingly optimistic about the company’s pipeline and encouraging regulatory progress for its flu vaccine.
But after such a sharp rally, it’s fair to ask whether there’s still an opportunity here to make some money
What comes next for Moderna? The investment case for Moderna isn’t just about COVID-19 vaccines anymore. It’s about what comes next.
Today, the company has three commercial products, multiple late-stage vaccine programs, and an expanding pipeline that stretches well beyond infectious diseases. Moderna is developing personalized cancer vaccines in partnership with Merck and pursuing therapies for rare genetic disorders. The company is now preparing for multiple product launches in 2027 and 2028, including seasonal flu, a flu/COVID-19 combination vaccine, and a norovirus vaccine.